164 related articles for article (PubMed ID: 37752548)
21. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
22. Progression of Carcinoid Heart Disease in the Modern Management Era.
Baron E; Szymanski C; Hergault H; Lepère C; Dubourg O; Hauguel-Moreau M; Mansencal N
J Am Heart Assoc; 2021 Dec; 10(23):e020475. PubMed ID: 34816734
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease.
Mansencal N; Mitry E; Pillière R; Lepère C; Gérardin B; Petit J; Gandjbakhch I; Rougier P; Dubourg O
Am J Cardiol; 2008 Apr; 101(7):1035-8. PubMed ID: 18359327
[TBL] [Abstract][Full Text] [Related]
24. Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features.
Rodríguez Laval V; Pavel M; Steffen IG; Baur AD; Dilz LM; Fischer C; Detjen K; Prasad V; Pascher A; Geisel D; Denecke T
Neuroendocrinology; 2018; 106(2):139-147. PubMed ID: 28384635
[TBL] [Abstract][Full Text] [Related]
25. Carcinoid heart disease--a hidden complication of neuroendocrine tumours.
Dero I; De Pauw M; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Roeyen G; Van Cutsem E; Van Hootegem P; Van Laethem JL; Verslype C; Peeters M
Acta Gastroenterol Belg; 2009; 72(1):34-8. PubMed ID: 19402369
[TBL] [Abstract][Full Text] [Related]
26. Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series.
Chan DL; Pavlakis N; Crumbaker M; Lawrence B; Barber C; Price TJ; Michael M; Oberg K
Asia Pac J Clin Oncol; 2022 Jun; 18(3):209-216. PubMed ID: 33852771
[TBL] [Abstract][Full Text] [Related]
27. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality.
Dobson R; Burgess MI; Valle JW; Pritchard DM; Vora J; Wong C; Chadwick C; Keevi B; Adaway J; Hofmann U; Poston GJ; Cuthbertson DJ
Br J Cancer; 2014 Oct; 111(9):1703-9. PubMed ID: 25211656
[TBL] [Abstract][Full Text] [Related]
28. Update in carcinoid heart disease - the heart of the matter.
Oleinikov K; Korach A; Planer D; Gilon D; Grozinsky-Glasberg S
Rev Endocr Metab Disord; 2021 Sep; 22(3):553-561. PubMed ID: 33443717
[TBL] [Abstract][Full Text] [Related]
29. Carcinoid Heart Disease: From Pathophysiology to Treatment--'Something in the Way It Moves'.
Grozinsky-Glasberg S; Grossman AB; Gross DJ
Neuroendocrinology; 2015; 101(4):263-73. PubMed ID: 25871411
[TBL] [Abstract][Full Text] [Related]
30. Four decades of experience with carcinoid heart disease: An analysis of 84 patients.
Levy S; Korse CE; de Groot ACA; Meijer RCA; Tesselaar MET; Valk GD
J Neuroendocrinol; 2022 Oct; 34(10):e13199. PubMed ID: 36256859
[TBL] [Abstract][Full Text] [Related]
31. Incidence and evolution of carcinoid syndrome in the heart.
Moyssakis IE; Rallidis LS; Guida GF; Nihoyannopoulos PI
J Heart Valve Dis; 1997 Nov; 6(6):625-30. PubMed ID: 9427132
[TBL] [Abstract][Full Text] [Related]
32. Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force).
Hofland J; Lamarca A; Steeds R; Toumpanakis C; Srirajaskanthan R; Riechelmann R; Panzuto F; Frilling A; Denecke T; Christ E; Grozinsky-Glasberg S; Davar J;
J Neuroendocrinol; 2022 Mar; 34(3):e13060. PubMed ID: 34825753
[TBL] [Abstract][Full Text] [Related]
33. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease.
Zuetenhorst JM; Korse CM; Bonfrer JM; Bakker RH; Taal BG
Br J Cancer; 2004 Jun; 90(11):2073-9. PubMed ID: 15150565
[TBL] [Abstract][Full Text] [Related]
34. Activin A in carcinoid heart disease: a possible role in diagnosis and pathogenesis.
Bergestuen DS; Edvardsen T; Aakhus S; Ueland T; Oie E; Vatn M; Aukrust P; Thiis-Evensen E
Neuroendocrinology; 2010; 92(3):168-77. PubMed ID: 20720391
[TBL] [Abstract][Full Text] [Related]
35. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
[TBL] [Abstract][Full Text] [Related]
36. Morphologic features of carcinoid heart disease as assessed by three-dimensional transesophageal echocardiography.
Nalawadi SS; Siegel RJ; Wolin E; Yu R; Trento A; Shiota T; Tolstrup K; Luthringer D; Gurudevan S
Echocardiography; 2010 Oct; 27(9):1098-105. PubMed ID: 21039812
[TBL] [Abstract][Full Text] [Related]
37. Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.
Noordzij W; van Beek AP; Tio RA; van der Horst-Schrivers AN; de Vries EG; van Ginkel B; Walenkamp AM; Glaudemans AW; Slart RH; Dierckx RA
PLoS One; 2014; 9(11):e112278. PubMed ID: 25397775
[TBL] [Abstract][Full Text] [Related]
38. Development of severe intrapulmonary shunting in a patient with carcinoid heart disease after closure of a persistent foramen ovale: a case report.
Schüttler D; Mourouzis K; Auernhammer CJ; Rizas KD
Eur Heart J Case Rep; 2021 Dec; 5(12):ytab494. PubMed ID: 35047738
[TBL] [Abstract][Full Text] [Related]
39. A 33-year follow-up after valvular surgery for carcinoid heart disease.
Bergsten J; Flachskampf FA; Lundin L; Öhagen P; Albåge A
Eur Heart J Cardiovasc Imaging; 2022 Mar; 23(4):524-531. PubMed ID: 33899077
[TBL] [Abstract][Full Text] [Related]
40. Results of Contemporary Valve Surgery in Patients with Carcinoid Heart Disease.
Kuntze T; Owais T; Secknus MA; Kaemmerer D; Baum R; Girdauskas E
J Heart Valve Dis; 2016 May; 25(3):356-363. PubMed ID: 27989047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
